Purpose of this Study
We are doing this study to compare the usual treatment of Nivolumab and ipilimumab to using the usual treatment plus surgery for people with sarcomatoid mesothelioma. We want to find out if adding surgery to the immunotherapy regimen is effective in stabilizing this type of cancer.
Who Can Participate?
Eligibility
Adults ages 18+ who are diagnosed with sarcomatoid mesothelioma.
For more information about who can join this study, please contact the study team at jennifer.j.brown@duke.edu.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will go through a screening period that lasts up to 4 weeks to find out if you are eligible. During this screening period, you will:
- Have a physical exam
- Have blood draws
- Have a tumor biopsy
- Have imaging (CT or PET scan, or MRI)
- Give urine samples
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid Mesothelioma
Principal Investigator
Jeffrey
Clarke
Protocol Number
PRO00113814
NCT ID
NCT05647265
Phase
N/A
Enrollment Status
Open to Enrollment